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Background: Patients on long-term hemodialysis are at a significantly higher risk for catheter-
related bloodstream infections (BSI) than the general population. These infections are generally
caused by Gram-positive organisms, especially Staphylococcus aureus. In the present study, we
evaluated the antimicrobial susceptibility patterns of S. aureus causing BSI in dialysis patients
compared to those causing BSI in other patient populations.
Methods: The potencies of daptomycin and various comparator agents were evaluated by
reference broth microdilution methods for S. aureus bloodstream isolates from dialysis patients
(606 strains) in 43 hospitals in North America and Europe. Susceptibility patterns for the dialysis
isolate set were compared to those S. aureus causing BSI in other patient populations in the same
hospitals and time period.
Results: Daptomycin was highly potent against S. aureus causing bacteremia in dialysis patients
(MIC50/MIC90, 0.25/0.5 mg/ml). Vancomycin (MIC50/MIC90, 1/1 mg/ml) and linezolid (MIC50/
MIC90, 2/2 mg/ml) showed similar potency, and overall susceptibility rates for the three anti-
biotics were 99.8—100.0% susceptible. Linezolid and vancomycin were four- to eight-fold less
potent than daptomycin.
Conclusions: The overall susceptibility patterns of S. aureus strains from dialysis patients were
very similar to those of non-dialysis patients.
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* Corresponding author. Tel.: +1 319 665 3370; fax: +1 319 665 3371.
E-mail address: helio-sader@jmilabs.com (H.S. Sader).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.07.006Introduction
Patients on long-term hemodialysis are at a significantly
higher risk for catheter-related bloodstream infectionsPublished by Elsevier Ltd. All rights reserved.
292 H.S. Sader et al.(BSI). Infection, mainly septicemia, is second to cardiovas-
cular disease as the leading cause of death in patients with
end-stage renal disease (ESRD) in the USA.1—3 In fact, cathe-
ters account for a significant proportion of septicemia in this
population. In a prospective study performed a decade ago,
40% of hemodialysis patients dialyzed by central venous
catheters developed potentially life-threatening bacteremic
complications, including infective endocarditis, septicemia,
and osteomyelitis.4 In a more recent study,5 the overall
incidence of septicemia was 10.4 first events per 100
patient-years. Compared with hemodialysis patients with
fistulas for dialysis access, peritoneal dialysis patients and
hemodialysis patients dialyzed with synthetic grafts had
similar risks of septicemia. Even with adjustment for differ-
ences in comorbidity, the risk of septicemia was almost twice
as high in patients using central venous catheters, whether
tunneled or non-tunneled.5 Similar rates have been reported
in a multicenter, prospective study of patients beginning
maintenance dialysis therapy in the USA between 1995 and
1998.6
These infections are generally caused by Gram-positive
organisms, especially Staphylococcus aureus, which has been
associated with the most devastating metastatic complica-
tions due to the tropism for heart valves and bone. Further-
more, vascular access-related BSI and related complications
requiring hospitalization account for nearly one-third of the
cost of ESRD management, with reported mortality rates of
12—26%.7,8
Daptomycin is a lipopeptide antimicrobial agent with
potent in vitro activity against Gram-positive cocci.9—11
Daptomycin does not exhibit cross-resistance with other
known classes of antimicrobials and also has a low risk for
development of spontaneous mutational resistance. Indeed,
daptomycin has been shown to be active against methicillin-
resistant S. aureus (MRSA), S. aureus resistant to linezolid or
quinupristin/dalfopristin, vancomycin-resistant enterococci
(VRE), and macrolide-resistant streptococci.11—13 Daptomy-
cin was approved by the United States Food and Drug Admin-
istration (USA-FDA) and by the European Medicines Agency
(EMEA) for the treatment of complicated skin and skin struc-
ture infections (cSSSI) caused bymethicillin-susceptible and -
resistant S. aureus, groups A and B b-hemolytic streptococci,
and for vancomycin-susceptible Enterococcus faecalis. This
compound has also been approved for the treatment of S.
aureus bacteremia and right-sided infective endocarditis.14
In the present study, we evaluated the antimicrobial suscept-
ibility patterns of S. aureus causing BSI in dialysis patients
compared to those causing BSI in other patient populations.Table 1 Daptomycin MIC distributions for Staphylococcus aureus
causing BSI in two non-dialysis patient populations
Organism group (No. of isolates) Number of isolates (cumula
0.12 0.25
Dialysis patients (606) 28 (4.6) 412 (72.6)
Control groupa (1212) 55 (4.5) 869 (76.2)
Bloodstream infectionb (12 191) 552 (4.5) 8569 (74.8)
BSI, blood stream infection; MIC, minimum inhibitory concentration.
a For each strain from a dialysis patient, two strains (2:1) from BSI in no
b Includes all S. aureus strains collected from BSI in North America aMaterials and methods
As part of the Daptomycin Surveillance Program, 606 S.
aureus strains causing BSI in dialysis patients were collected
from 43 hospitals in North America and Europe in 2002—2006.
Susceptibility patterns of strains from dialysis patients were
compared to those of 1212 S. aureus strains (randomized at
2:1) causing BSI in non-dialysis patients. For each strain from
a dialysis patient, two strains from BSI in non-dialysis patients
hospitalized in the same hospital and time period were
included as the control group. A third group of strains used
for comparison included all S. aureus strains collected by the
JMI Laboratories (North Liberty, IA, USA) from BSI in North
American and European medical centers in the 2002—2006
period, excluding the group of strains from dialysis patients
(12 191 strains).
Daptomycin and more than 20 comparator agents were
tested using the Clinical Laboratory Standards Institute (CLSI)
M7-A7 broth microdilution method.15,16 All strains were
tested in validated, brothmicrodilution panels manufactured
by TREK Diagnostics (Cleveland, OH, USA). Mueller—Hinton
broth adjusted to contain physiological levels of calcium
(50 mg/l) was used when testing daptomycin. The USA-FDA
and CLSI approved daptomycin susceptibility breakpoint for
S. aureus (1 mg/ml) was applied. The following quality
control (QC) organisms were concurrently tested: E. faecalis
ATCC 29212, S. aureus ATCC 29213, and Streptococcus pneu-
moniae ATCC 49619; all results were within published QC
ranges.16
Results
Daptomycin was highly active against S. aureus isolates from
dialysis patients (MIC50, 0.25 mg/ml; MIC90, 0.5 mg/ml) with
only one strain (0.16%) showing decreased susceptibility to
this compound (MIC of 2 mg/ml; Table 1). Daptomycin MIC
distribution of S. aureus BSI strains from dialysis patients was
very similar to those of the other two groups of S. aureus
strains evaluated (control group and all BSI strains) with
72.6—76.2% of strains inhibited at 0.25 mg/ml and 98.8—
99.5% inhibited at 0.5 mg/ml of daptomycin (Table 1).
Susceptibility rates for most of the antimicrobial agents
were similar among the S. aureus groups evaluated (Table 2).
Oxacillin susceptibility rates were relatively low among all
groups (60.4—61.8% susceptible). Erythromycin (44.6—47.0%
susceptibility), levofloxacin (59.9—62.0%), and clindamycin
(75.2—79.0%) also exhibited limited activity among all groupsisolated from BSI in dialysis patients when compared to those
tive %) inhibited at daptomycin MIC (mg/ml) of:
0.5 1 2 4
159 (98.8) 6 (99.8) 1 (100.0) -
282 (99.5) 6 (100.0) - -
2979 (99.3) 85 (>99.9) 5 (>99.9) 1 (100.0)
n-dialysis patients hospitalized in the same hospital and time period.
nd Europe from January 2002 to December 2006.
Table 2 Antimicrobial susceptibility patterns of S. aureus isolated from BSI in dialysis patients compared to those causing BSI in
non-dialysis patients (two groups)
Antimicrobial agents Dialysis (606) Control (1212) BSI (12 191)
MIC90 % susceptible MIC90 % susceptible MIC90 % susceptible
Daptomycin 0.5 99.8a 0.5 100.0 0.5 >99.9
Oxacillin >2 60.4 >2 60.6 >2 61.8
Erythromycin >8 47.0 >8 45.7 >8 44.6
Clindamycin >8 78.5 >8 79.0 >8 75.2
Levofloxacin >4 60.9 >4 59.9 >4 62.0
Mupirocin 4 94.2b 4 95.7b 4 96.0b
Trimethoprim/sulfamethoxazole 0.5 98.2 0.5 97.3 0.5 97.0
Quinupristin/dalfopristin 0.5 99.7 0.5 99.5 0.5 99.8
Linezolid 2 99.8c 2 100.0 2 >99.9
Vancomycin 1 100.0 1 100.0 1 >99.9d
BSI, blood stream infection; MIC, minimum inhibitory concentration.
a One non-susceptible strain with daptomycin MIC at 2 mg/ml.
b MIC 8 mg/ml.
c One non-susceptible strain with linezolid MIC at 8 mg/ml.
d Four non-susceptible strains with vancomycin MIC at 4 mg/ml.
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aureus strains from dialysis patients (94.2% susceptible at
8 mg/ml) compared to the other two groups (95.7—96.0%).
Daptomycin (MIC50 of 0.25 mg/ml and MIC90 of 0.5 mg/ml),
vancomycin (MIC50 and MIC90 of 1 mg/ml), and linezolid (MIC50
and MIC90 of 2 mg/ml) were the most active compounds
tested. Although these compounds showed similar suscept-
ibility rates (99.8—100.0%), daptomycin was four- to eight-
fold more active than vancomycin or linezolid (Table 2).
Resistance to oxacillin did not adversely affect the activity
of these compounds (data not shown). S. aureus isolates from
the control group (randomized at 2:1 ratio; 1212 strains)
exhibited susceptibility patterns very similar to those of
strains from dialysis patients (Table 2). A third group of
strains (BSI group), which included all S. aureus BSI strains
collected by the monitor during the same time period, also
showed susceptibility patterns comparable to those of strains
from dialysis patients and the control group (Table 2).
Daptomycin MIC values higher than the susceptible break-
point of 1 mg/ml were observed in only six strains of the large
group (0.05% of 12 191 strains). Five strains had a daptomycin
MIC value of 2 mg/ml. Only one strain had a MIC value of 4 mg/
ml for daptomycin (<0.01%). Isolateswith a daptomycinMIC of
2 mg/ml showed vancomycin MIC values of 2 mg/ml, and the
strain with daptomycin MIC of 4 mg/ml exhibited vancomycin
MICof 4 mg/ml (vancomycin-intermediateorVISAphenotype).
Four strains with decreased susceptibility to vancomycin
were observed in the all BSI group, each having a vancomycin
MIC of 4 mg/ml. Three of those strains were susceptible to
daptomycin (MIC 0.5—1 mg/ml), while the fourth strain was
the daptomycin isolate with a MIC value of 4 mg/ml. More-
over, five strains showed elevated linezolid MIC values, three
strains with a MIC value of 4 mg/ml (susceptible) and two S.
aureus isolates that were non-susceptible to linezolid, one
each with a MIC value of 8 mg/ml and 16 mg/ml. All isolates
with elevated linezolid MIC values (4 mg/ml) were suscep-
tible to daptomycin (MIC 0.25—0.5 mg/ml) and vancomycin
(MIC 1 mg/ml). The linezolid non-susceptible strains (MIC
8 mg/ml) were isolated in the USA in Seattle, Washington,and Des Moines, Iowa, and both had a G2576T mutation in
domain V of the 23S rRNA.
Discussion
S. aureus is a leading cause of BSI and other invasive infec-
tions, and dialysis patients are especially vulnerable to S.
aureus infections, frequently those caused by antimicrobial-
resistant strains (MRSA). It is estimated that, in 2005, the
incidence of invasive MRSA infection among dialysis patients
was 45.2 cases per 1000 population in the USA.17 Persons
receiving dialysis can be at higher risk for infection with
invasive MRSA compared with the general population, in
which rates of invasive MRSA have ranged from 0.2 to 0.4
infections per 1000 population.18 Furthermore, infections
represent the second most common cause of death in
patients with ESRD, accounting for nearly 14% of deaths.18
Antimicrobial treatment for dialysis-associated infections
is one of the factors increasing the prevalence of antimicro-
bial resistance. MRSA strains of healthcare origin are typically
multidrug-resistant. In the USA, five of six first patients
reported with VISA had received dialysis, and the first case
of vancomycin-resistant S. aureus (VRSA) was a dialysis
patient.17,19 Vancomycin clearances vary substantially
according to the type of dialysis. The compound is not
significantly dialyzable when hemodialysis is performed using
a low fluxmembrane such as cuprophan, but it is considerably
dialyzable when hemodialysis is performed using a high flux
membrane such as polysulfone, polyacrylonitrile, and poly-
methylmethacrylate. Continuous renal replacement therapy
also increases total body clearance of vancomycin. However,
quantification of vancomycin removal is difficult to estimate
with any type of hemodialysis, and monitoring plasma levels
of the drug is highly recommended.20 Inappropriate dosage
adjustmentmay lead to either toxic side effects levels or long
periods of low trough levels, which may facilitate the emer-
gence of vancomycin-resistant strains.19—22
Daptomycin plasma protein binding is approximately
92% and its elimination is primarily achieved by renal
294 H.S. Sader et al.excretion of unchanged drug.23 The mean urinary recovery
over a 24-hour period is 50% to 60% of the administered
dose in healthy adults. The recommended dose of dapto-
mycin is 4 mg/kg/day for treatment of cSSSI and 6 mg/kg/
day for treatment of bacteremia and endocarditis. It is
administered intravenously once daily for patients with
creatinine clearances 30 ml/min. Hence, in patients
with reduced renal function (creatinine clearances
<30 ml/min), including those receiving hemodialysis or
continuous ambulatory peritoneal dialysis, the recom-
mended dose interval is 48 hours.23 In addition, more
recent studies indicate that extended daily dialysis, an
extracorporeal renal replacement therapy that is increas-
ingly used in intensive care units, eliminates daptomycin
effectively and to a larger extent than intermittent hemo-
dialysis. Thus, patients on extended daily dialysis may
require higher daptomycin doses than those on intermit-
tent hemodialysis.24
In the present study, vancomycin, linezolid, and dapto-
mycin were the most active compounds tested against S.
aureus causing BSI in dialysis patients, as well as against a
large collection of S. aureus BSI strains collected in North
America and Europe. Vancomycin has been the standard
antimicrobial therapy for serious MRSA infections since
the early 1980 s, when MRSA emerged as a significant noso-
comial pathogen.25 However, vancomycin has demonstrated
slower in vitro bactericidal activity and suboptimal clinical
response compared with antistaphylococcal beta-lac-
tams.25,26
Vancomycin-susceptible MRSA strains show a considerable
heterogeneity in vitro with respect to vancomycin MIC and
killing, and these differences appear to affect the clinical
efficacy and the probability of successful treatment of MRSA
BSI. Although the clinical importance of bactericidal activity
in the treatment of most infections remains controversial,
antimicrobial treatments that provide bactericidal therapy
have been shown to be superior to bacteriostatic regimens in
the treatment of S. aureus BSI, especially in endocarditis.25—
27 Sakoulas et al. evaluated 30 MRSA strains from 30 patients
with bacteremia and showed a statistically significant rela-
tionship between treatment success with vancomycin and
decrease in vancomycin MIC values (0.5 mg/ml compared to
1—2 mg/ml; p = 0.02) and the degree of killing (reduction in
log10 CFU/ml).
26
In contrast to vancomycin and linezolid, daptomycin has
rapid, concentration-dependent bactericidal activity
against S. aureus and has demonstrated excellent results
in the treatment of S. aureus BSI.11,27 This in vitro bacter-
icidal activity is maintained at high inoculum concentrations
and against bacteria in the stationary growth phase.
Furthermore, daptomycin has demonstrated a prolonged,
concentration-dependent post-antibiotic effect,10 and good
results in treating staphylococcal (Staphylococcus epider-
midis and S. aureus) biofilms in a central venous catheter
model.28
In summary, daptomycin exhibited sustained activity
against a large collection of S. aureus collected from BSI
(2002—2006 sample), including strains from dialysis patients.
Because of its excellent anti-S. aureus spectrum, high
potency, and rapid bactericidal activity, daptomycin repre-
sents an excellent treatment option for BSI caused by S.
aureus in at-risk patients such as those on hemodialysis.Acknowledgements
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